| Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase HE Bryant, N Schultz, HD Thomas, KM Parker, D Flower, E Lopez, S Kyle, ... Nature 434 (7035), 913-917, 2005 | 5926 | 2005 |
| Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM I Hickson, Y Zhao, CJ Richardson, SJ Green, NMB Martin, AI Orr, ... Cancer research 64 (24), 9152-9159, 2004 | 1436 | 2004 |
| DNA repair dysregulation from cancer driver to therapeutic target NJ Curtin Nature Reviews Cancer 12 (12), 801-817, 2012 | 1215 | 2012 |
| Anticancer chemosensitization and radiosensitization by the novel poly (ADP-ribose) polymerase-1 inhibitor AG14361 CR Calabrese, R Almassy, S Barton, MA Batey, AH Calvert, ... Journal of the National Cancer Institute 96 (1), 56-67, 2004 | 599 | 2004 |
| Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441 Y Zhao, HD Thomas, MA Batey, IG Cowell, CJ Richardson, RJ Griffin, ... Cancer research 66 (10), 5354-5362, 2006 | 546 | 2006 |
| Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer SA Eccles, EO Aboagye, S Ali, AS Anderson, J Armes, F Berditchevski, ... Breast Cancer Research 15, 1-37, 2013 | 542 | 2013 |
| Phase I study of the poly (ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors R Plummer, C Jones, M Middleton, R Wilson, J Evans, A Olsen, N Curtin, ... Clinical cancer research 14 (23), 7917-7923, 2008 | 506 | 2008 |
| Therapeutic applications of PARP inhibitors: anticancer therapy and beyond NJ Curtin, C Szabo Molecular aspects of medicine 34 (6), 1217-1256, 2013 | 447 | 2013 |
| Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly (ADP-ribose) polymerase-1 SJ Veuger, NJ Curtin, CJ Richardson, GCM Smith, BW Durkacz Cancer research 63 (18), 6008-6015, 2003 | 445 | 2003 |
| Poly (ADP-ribose) polymerase inhibition: past, present and future NJ Curtin, C Szabo Nature Reviews Drug Discovery 19 (10), 711-736, 2020 | 438 | 2020 |
| Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers J de Bono, RK Ramanathan, L Mina, R Chugh, J Glaspy, S Rafii, S Kaye, ... Cancer discovery 7 (6), 620-629, 2017 | 413 | 2017 |
| The role of PARP in DNA repair and its therapeutic exploitation M Javle, NJ Curtin British journal of cancer 105 (8), 1114-1122, 2011 | 395 | 2011 |
| Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly (ADP-ribose) polymerase AW White, R Almassy, AH Calvert, NJ Curtin, RJ Griffin, Z Hostomsky, ... Journal of medicinal chemistry 43 (22), 4084-4097, 2000 | 395 | 2000 |
| Preclinical selection of a novel poly (ADP-ribose) polymerase inhibitor for clinical trial HD Thomas, CR Calabrese, MA Batey, S Canan, Z Hostomsky, S Kyle, ... Molecular cancer therapeutics 6 (3), 945-956, 2007 | 355 | 2007 |
| PARP inhibitors for cancer therapy NJ Curtin Expert Reviews Molecular Medicine 7 (4), 1-20, 2005 | 328 | 2005 |
| Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly (ADP-ribose … A Mukhopadhyay, A Elattar, A Cerbinskaite, SJ Wilkinson, Y Drew, S Kyle, ... Clinical cancer research 16 (8), 2344-2351, 2010 | 320 | 2010 |
| Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition N Johnson, YC Li, ZE Walton, KA Cheng, D Li, SJ Rodig, LA Moreau, ... Nature medicine 17 (7), 875-882, 2011 | 316 | 2011 |
| Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2 Y Drew, EA Mulligan, WT Vong, HD Thomas, S Kahn, S Kyle, ... Journal of the national cancer institute 103 (4), 334-346, 2011 | 301 | 2011 |
| Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly (adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines CA Delaney, LZ Wang, S Kyle, AW White, AH Calvert, NJ Curtin, ... Clinical cancer research 6 (7), 2860-2867, 2000 | 287 | 2000 |
| Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor TG Davies, J Bentley, CE Arris, FT Boyle, NJ Curtin, JA Endicott, ... Nature structural biology 9 (10), 745-749, 2002 | 286 | 2002 |
Huw ThomasSenior Research AssociateZweryfikowany adres z ncl.ac.uk